Chrono Therapeutics scores $47.6 mln Series B
Hayward, California-based digital drug therapy company Chrono Therapeutics has raised $47.6 million in Series B financing. Kaiser Permanente Ventures led the round with participation from other investors that included Endeavour Vision, Xeraya Capital, Labuan Ltd, Emergent Medical Partners, Canaan Partners, 5AM Ventures, Fountain Healthcare Partners, GE Ventures, Hikma Ventures, Cota Capital and Mission Bay Capital. In addition to the funding, Liz Rockett, director of Kaiser Permanente Ventures, has been added to Chrono Therapeutics' board of directors.
9 September 2016•1 min read
